- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.10. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08. | Apimeds partners with University of Alabama for pharmaceutical innovation | 2 | Investing.com | ||
| 25.08. | Apimeds kooperiert mit University of Alabama bei Pharma-Innovation | 2 | Investing.com Deutsch | ||
| 19.08. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.07. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Apimeds Pharmaceuticals stärkt Management mit zwei neuen Führungskräften | - | Investing.com Deutsch | ||
| 15.07. | Apimeds Pharmaceuticals adds two key executives to leadership team | 3 | Investing.com | ||
| APIMEDS PHARMACEUTICALS US Aktie jetzt für 0€ handeln | |||||
| 05.06. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.05. | Apimeds Pharmaceuticals US, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 4 | SEC Filings | ||
| 20.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.05. | Apimeds Pharmaceuticals US, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 16.05. | D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. in connection with its $13.5 Million Initial Public Offering | 540 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in... ► Artikel lesen | |
| 12.05. | Apimeds Pharmaceuticals US, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering | 190 | GlobeNewswire (Europe) | Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the... ► Artikel lesen | |
| 09.05. | Apimeds Pharmaceuticals starts trading at $4 per share in line with IPO pricing | 1 | Investing.com | ||
| 09.05. | Apimeds Pharmaceuticals startet Handel bei 4 US-Dollar je Aktie gemäß Börsengang-Preis | 2 | Investing.com Deutsch | ||
| 09.05. | Inflammation drug developer Apimeds Pharmaceuticals US prices IPO at $4.00, the low end of the range | 3 | Renaissance Capital | ||
| 05.05. | IPO Roundup: American Integrity Insurance, Apimeds Pharmaceuticals and more | 1 | Seeking Alpha | ||
| 02.05. | Apimeds Pharmaceuticals US, Inc. - 10-K/A, Annual Report | - | SEC Filings |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,97 | +42,36 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| QIAGEN | 41,860 | -1,29 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,290 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| EVOTEC | 7,124 | +2,18 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,170 | 0,00 % | Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday | ||
| MAPLIGHT THERAPEUTICS | 18,050 | 0,00 % | MapLight Therapeutics Prices IPO Of 14.75 Mln Shares At $17.00/shr | WASHINGTON (dpa-AFX) - MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company focused on
improving the lives of patients suffering from debilitating central nervous
system... ► Artikel lesen | |
| NUVALENT | 97,95 | +4,88 % | Piper Sandler erhöht Kursziel für Nuvalent auf 128 US-Dollar wegen ALK-Potenzial | ||
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 186,82 | +7,53 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 58,53 | +2,16 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ZENAS BIOPHARMA | 31,500 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis | - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,590 | -42,75 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| BIONTECH | 91,25 | +0,50 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,470 | +1,04 % | Summit Therapeutics: A Risky Bet in the Biotech Arena? | ||
| 89BIO | 14,835 | +0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen |
APIMEDS PHARMACEUTICALS US INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,880 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APIMEDS PHARMACEUTICALS US INC finden Sie auf Wallstreet Online.